| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators New England Journal of Medicine 345 (7), 494-502, 2001 | 8611 | 2001 |
| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone ... The Lancet 368 (9541), 1096-1105, 2006 | 2225 | 2006 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1329 | 2018 |
| Low-dose methotrexate for the prevention of atherosclerotic events PM Ridker, BM Everett, A Pradhan, JG MacFadyen, DH Solomon, ... New England Journal of Medicine 380 (8), 752-762, 2019 | 1126 | 2019 |
| 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult TJ Anderson, J Grégoire, RA Hegele, P Couture, GBJ Mancini, ... Canadian Journal of Cardiology 29 (2), 151-167, 2013 | 1084 | 2013 |
| 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult–2009 recommendations J Genest, R McPherson, J Frohlich, T Anderson, N Campbell, ... Canadian Journal of Cardiology 25 (10), 567-579, 2009 | 1071 | 2009 |
| 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult–2009 recommendations J Genest, R McPherson, J Frohlich, T Anderson, N Campbell, ... Canadian Journal of Cardiology 25 (10), 567-579, 2009 | 1071 | 2009 |
| 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult TJ Anderson, J Grégoire, GJ Pearson, AR Barry, P Couture, M Dawes, ... Canadian Journal of Cardiology 32 (11), 1263-1282, 2016 | 1042 | 2016 |
| Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children KA Nerenberg, KB Zarnke, AA Leung, K Dasgupta, S Butalia, K McBrien, ... Canadian Journal of Cardiology 34 (5), 506-525, 2018 | 697 | 2018 |
| Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of … AA Leung, K Nerenberg, SS Daskalopoulou, K McBrien, KB Zarnke, ... Canadian Journal of Cardiology 32 (5), 569-588, 2016 | 539 | 2016 |
| 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults GJ Pearson, G Thanassoulis, TJ Anderson, AR Barry, P Couture, N Dayan, ... Canadian journal of cardiology 37 (8), 1129-1150, 2021 | 508 | 2021 |
| Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children DM Rabi, KA McBrien, R Sapir-Pichhadze, M Nakhla, SB Ahmed, ... Canadian Journal of Cardiology 36 (5), 596-624, 2020 | 478 | 2020 |
| Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update J Genest, J Frohlich, G Fodor, R McPherson Cmaj 169 (9), 921-924, 2003 | 455 | 2003 |
| Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis BM Everett, AD Pradhan, DH Solomon, N Paynter, J MacFadyen, ... American heart journal 166 (2), 199-207. e15, 2013 | 443 | 2013 |
| Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults AA Leung, SS Daskalopoulou, K Dasgupta, K McBrien, S Butalia, ... Canadian Journal of Cardiology 33 (5), 557-576, 2017 | 420 | 2017 |
| Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions P Raggi, J Genest, JT Giles, KJ Rayner, G Dwivedi, RS Beanlands, ... Atherosclerosis 276, 98-108, 2018 | 407 | 2018 |
| Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association AS Volgman, LS Palaniappan, NT Aggarwal, M Gupta, A Khandelwal, ... Circulation 138 (1), e1-e34, 2018 | 404 | 2018 |
| Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction TA of the Safety The Lancet 358 (9282), 605-613, 2001 | 398 | 2001 |
| Adropin is a novel regulator of endothelial function F Lovren, Y Pan, A Quan, KK Singh, PC Shukla, M Gupta, M Al-Omran, ... Circulation 122 (11_suppl_1), S185-S192, 2010 | 379 | 2010 |
| MicroRNA-145 targeted therapy reduces atherosclerosis F Lovren, YI Pan, A Quan, KK Singh, PC Shukla, N Gupta, BM Steer, ... Circulation 126 (11_suppl_1), S81-S90, 2012 | 331 | 2012 |
Rob HegeleWestern University, Robarts Research InstituteVerified email at robarts.ca
